The Evolving Role of Immunotherapy in NSCLC: Pearls for Clinical Practice

Access Course

 

890347.jpg?interpolation=lanczos-none&resize=300:*Faculty discuss recent and ongoing clinical trials that affect clinical decisions with the use of immunotherapy in NSCLC.


This activity is intended for hematology/oncology specialists and pharmacists.
 

The goal of this activity is to improve knowledge of clinical trial designs and practical application of data in order to improve management of patients with non-small cell lung cancer (NSCLC).

 

 

 

Approximate Time to Complete: 30 minutes

 

Credit Available: Feb. 27, 2018 - Feb. 27, 2019

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • increase knowledge regarding the relevance of clinical trial design in patient selection and preferences in patients with advanced NSCLC
  • Increase knowledge regarding clinical trial data on the use of immunotherapies in patients with advanced NSCLC
Accreditation Council For Continuing Medical Education
AMA PRA Category 1 Credit(s)â„¢: 0.50
Accreditation Council for Pharmacy Education
CEU: 0.50
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 0.50